Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose

On July 13, 2026, the FDA approved a subcutaneous starting dose regimen for lecanemab-irmb (Leqembi; Eisai/Biogen), allowing patients with early Alzheimer disease to initiate treatment at home via weekly self-injection for the first time. The decision eliminates the prior requirement for 18 months of intravenous infusions before at-home dosing becomes an option.

Laura Nisenbaum, PhD, is the Interim Chief Science Officer at the Alzheimer's Drug Discovery Foundation, an organization that has long advocated for a precision medicine approach to Alzheimer disease treatment. Following the approval, NeurologyLive^® reached out to Dr. Nisenbaum for her reaction.

In this Q&A, she addressed what the approval means across the Alzheimer disease community, what clinicians should know about safely prescribing the subcutaneous starting dose, and how advances like this fit into the broader push toward combination therapy and long-term disease management.

NeurologyLive: Put in context what this approval means for Alzheimer community, including clinicians, patients, and caregivers

Laura Nisenbaum, PhD: This approval does not change what lecanemab does biologically, but it could change who is realistically able to start and remain on treatment.

By reducing reliance on infusion centers and opening the door to at-home administration, a subcutaneous starting dose could make treatment easier to incorporate into patients’ everyday lives. For patients and caregivers, that means less time, travel, and disruption. For clinicians, it means a more practical way to deliver treatment. This is an important step toward making disease-modifying treatment more accessible and sustainable.

For clinicians who treat those with AD, what should they know about this SC starting dose and how to safely and effectively prescribe it?

The key point for clinicians is that subcutaneous administration changes how lecanemab is delivered, not how patients should be monitored.

Patients still require careful MRI monitoring during treatment initiation to screen for ARIA, along with careful counseling about risk, particularly for APOE4 homozygotes. The autoinjector may reduce the burden of infusions, but it does not reduce the need for clinical vigilance.

How can approval like this springboard future drug development and another step closer to ultimately curing or managing Alzheimer disease?

Approvals like this help build the foundation for the next generation of Alzheimer’s treatment. As the ADDF has long emphasized, the future of care will likely require a precision approach that addresses the full pathobiology of the disease through combining different therapies, much like the approach that transformed cancer care. But to make that future possible, each therapy must be practical, scalable, and sustainable over the long term.

With much of the Alzheimer’s drug pipeline now focused on pathways beyond amyloid and tau, scalable delivery options will be essential as we tailor combinations of therapies to each patient’s biology. We may not be talking about a single cure, but advances like this move us closer to managing Alzheimer’s as a complex, treatable disease.